SGHT
A cleaner path for TearCare
Sight Sciences says the FDA expanded the indications for its TearCare System, a move that makes the treatment the first one specifically cleared to improve signs of meibomian gland dysfunction, or MGD. Translation: the company just got a bigger lane for a product already in the market.
Why investors should care
Regulatory labels are boring right up until they’re not. A broader indication can make it easier for doctors to use the device, for payers to justify coverage, and for sales teams to pitch the thing without sounding like they’re trying to sneak a bigger claim through the back door.
For SGHT, this is the kind of news that can matter because it may:
- expand the addressable market for TearCare
- support adoption by eye care professionals
- strengthen the company’s story around dry eye treatment
Big picture
No, this isn’t a moonshot headline. But it is the sort of FDA win that can quietly nudge a medtech company from “interesting” to “more commercially viable.” And in biotech-adjacent land, that’s often where the real money starts to show up.